Cost-Effectiveness of Adjuvanted Influenza Vaccine Compared with Standard and High-Dose Influenza Vaccines for Persons Aged ≥50 Years in Spain

Cost-Effectiveness of Adjuvanted Influenza Vaccine Compared with Standard and High-Dose Influenza Vaccines for Persons Aged ≥50 Years in Spain

Background: The prevalence of chronic conditions that increase the risk of influenza complications is high among individuals aged ≥50 years, and evidence suggests age-related changes in immune responses to vaccines begin to decline at this age. Persons aged 50–59 years have high rates of influenza i...

Full description

Saved in:
Bibliographic Details
Main Authors: Alberto Perez-Rubio, Roberto Flores, Jesus Ruiz Aragon, Javier Sanchez, Sergio Marquez-Peláez, Piedad Alvarez, Andres Osorio Muriel, Joaquin Mould-Quevedo
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Vaccines
Subjects:
influenza
vaccination
Spain
cost-effectiveness
adjuvanted
high-dose
Online Access:https://www.mdpi.com/2076-393X/13/3/323
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items